NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Next Generation SedLine ® brain function monitoring for pediatric patients (1-18 years of age). With ...

Masimo has made a name for itself as a prolific purveyor of noninvasive patient monitoring technologies, from the SET pulse oximeter to the recently CE-marked Rainbow SuperSensor, which continuously ...

Masimo CorpMASI recently announced that its SedLine brain function monitor has been selected by Penn Highlands DuBois, a health centre with one of the best hospital safety scores (according to ...

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today FDA clearance of Next Generation SedLine ® brain function monitoring. SedLine helps clinicians monitor the state of the brain ...

Noting the unique nature of pediatric brains, which are still developing, the importance that standard anesthesia practice places on minimizing the dosage of drugs needed to maintain anesthesia, and ...

EEG-Guided Anesthesia Using Masimo Technology Significantly Reduced Pediatric Anesthesia Emergence Delirium, Time to Emergence and Discharge, and Cost of Care by Minimizing Sevoflurane Exposure ...

Irvine-based Masimo Corp., which makes patient monitoring devices, said a study found one of its products effectively monitored babies and toddlers undergoing surgeries. Researchers wanted to measure ...

Two young (11-week-old) pigs underwent sole propofol anaesthesia as part of an experimental study. The depth of anaesthesia was evaluated both clinically and using the ...

Masimo, a global medical technology company developing and producing a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and ...

(BUSINESS WIRE )--Masimo (NASDAQ: MASI) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women's Medical ...